TPST TEMPEST THERAPEUTICS INC

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma (RCC) at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

Poster presentation details:

   
Title: PPAR-α Antagonist Enhances Immunotherapy and Anti

  Angiogenic Therapy to Inhibit Murine Renal Cancer
Abstract Number:   3045
Date & Time: Monday, April 8, 2024; 1:30 – 5:00 p.m. PT
Session Title: Oncogenic Transcription Factors
Location: Poster Section 18



All regular abstracts are available for viewing via AACR’s online itinerary planner, located .

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at .

Investor & Media Contacts

Sylvia Wheeler

Wheelhouse Life Science Advisors

Aljanae Reynolds

Wheelhouse Life Science Advisors

 
i If approved by the FDA



EN
05/03/2024

Underlying

TPSTTEMPEST THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEMPEST THERAPEUTICS INC

 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Reports Second Quarter 2025 Financial Results and Provides Bus...

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines Agency (EMA) for amezalpat for the treatment of patients with HCCPresented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP) BRISBAN...

August 11, 2025 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat ...

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) ...

June 30, 2025 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Announces $4.6 Million Registered Direct Offering of Common St...

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000 shares of its common stock (or common stock equivalents), at an offering price of $6.25 per share of common stock (or commo...

June 11, 2025 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Receives Orphan Drug Designation from the European Medicines A...

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment optionsThe multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat combination therapy across multiple study endpoints, including overall survival in both the entire population ...

June 5, 2025 1 EN
 PRESS RELEASE
Free
TPST TEMPEST THERAPE...

Tempest Reports First Quarter 2025 Financial Results and Provides Busi...

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial adenomatous polyposis (FAP)Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of FAPGranted both Orphan Drug & Fast Track designations by FDA for Amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC) BRISBANE, Calif., May 13...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch